The acquired immunodeficiency syndrome (AIDS) is an epidemic disorder characterised by immuno examinations, with fundus photography performed every third day. Macular function tests were repeated at least weekly, and fluorescein angiograms were repeated on a weekly basis. All patients received ganciclovir 2 5 mg/kg intravenously every eight hours for a 21-day course. Two patients received more than one course in hospital. Two of the patients received subsequent maintenance therapy after finishing the 21-day course. It consisted of 5 mg/kg intravenously once per day for five of seven days every week administered through a Broviac catheter placed into a subclavian vessel.
Results
We found that six of 11 eyes (54.5%) improved their visual acuity by at least one line on the Snellen chart by the end of the 21-day course ( had both bilateral progressive scarring of the posterior pole and optic atrophy, resulting in a final visual acuity of no light perception. Thus ganciclovir improved or stabilised 81-7% of treated eyes. Two patients relapsed and required subsequent therapy more than once and lost an additional line of acuity on the Snellen chart; however, their final acuities remained better than their pretherapy acuities.
All patients had a drop in their white blood cell counts. In one case the dose of ganciclovir was decreased to 1 mg/kg intravenously every eight hours while the patient remained absolutely neutropenic (less than I x 109 white cells/I), and in another case the drug was terminated. The liver function values increased in five of the six patients; however, this did not interfere with the therapy regimen. Three of the six patients died after therapy, one from toxoplasmosis and two from disseminated CMV. One was lost to follow-up. These patients had not received maintenance therapy because they refused any further medications. One patient died from septicaemia while on maintenance therapy.
Discussion
Active CMV infection can be diagnosed by an increase in complement fixation antibodies, culture of the virus in serum, urine, saliva, or other body fluids, or biopsy confirmation of cells showing the classic histopathological picture. In the eye the virus has been isolated from tears" or conjunctiva'2 of patients with and without retinitis and does not correlate well with ocular symptoms. In patients with retinitis cultures of subretinal fluid and vitreous may be positive.' '6 In patients with panuveitis aqueous taps have yielded live virus.' 17 On occasion the diagnosis can be made by a vitreous tap and culture."" CMV retinitis has been found in 15% to 46% of AIDS patients in most series from the United States. 1'22 Once observed in these patients, the retinitis tends to be slowly but inexorably progressive, often affecting both eyes and ultimately causing complete blindness.
Therapy for cytomegalovirus retinitis has been for the most part unsuccessful. Limited experiences with transfer factor2' and antiviral drugs such as adenine arabinoside,24 floxacidine, and acyclovir have yielded only an occasional report of success.2'27 Clinically treatment with ganciclovir also did not appear to provide a permanent cure in the present series. Although this agent consistently halted the progression of the retinitis several days after initiation, and improved both the vision and the retina, these effects were maintained only during therapy and for a short time after drug therapy was withdrawn.2=3 Approximately three weeks after completion of a typical 21-day course, renewed CMV activity was observed in the retinas of cases 1, 2, 4, and 5.
Ganciclovir or BW B759U is an acyclic nucleoside analog of acyclovir. It is active against herpes simplex types I and II (HSV), varicella zoster virus (V2V), Epstein-Barr virus (EBV), and human cytomegalovirus (HCMV). In studies on human cytomegalovirus of strain AD169, BW B759U did not appear to affect virus early gene function. However, the synthesis of several late structural proteins was inhibited. 34 In the early patients reported here, no side effects were noted other than a decrease in the white blood cell count. In most patients it decreased slightly, and in two the treatment was reduced or stopped until the white blood cell count returned to normal. One case (3) experienced a transient decrease in the white blood cell count several days after finishing a first 10-day course of therapy. It could not be determined, however, whether this represented a delayed effect of the ganciclovir therapy or a consequence of other concurrent medications, the direct effect of the CMV itself, or the underlying immune deficiency. More interesting was that many of these patients stated they had an improved feeling of general wellbeing while on the drug. Those patients who had headaches noted improvement while on therapy. One can theorise that the medication may be able to enter the central nervous system and inhibit the virus despite animal studies suggesting poor CNS penetration.
Ganciclovir appears to slow or halt progression of CMV retinitis and allow for healing and visual improvement as shown by fundus photographs and macular fields. However, after therapy is discontinued the retinitis recurs, usually within three weeks. In addition recurrent episodes of CMV retinitis appear to respond more slowly and incompletely to treatment than do the initial episodes. As a result of the experience we report here, patients are being put on a maintenance schedule of 5 mg/kg intravenously in one dose, five times a week, after the initial course of therapy is completed. It is hoped that such a regimen will prevent recurrent retinitis.
